Input or output interoperability
DICOM is explicitly referenced in the described input, output, or workflow.
exact submission · checked 2026-09-01The model card does not establish every supported DICOM object, transfer method, or local interface.
FDA-cleared profile
QIR Suite
CASIS Cardiac Simulation & Imaging Software
Authorized purpose: View, post-process, and quantitatively evaluate cardiovascular MR images in DICOM format.
Evidence status: each field states its source quality, applicability, and review date. Research pending, information not established, and vendor documentation pending remain distinct outcomes.
Product overview
Start with the essentials
Authorized purpose: View, post-process, and quantitatively evaluate cardiovascular MR images in DICOM format.
Overview status: Source-reviewed overview
- What does this software do? Authorized purpose: View, post-process, and quantitatively evaluate cardiovascular MR images in DICOM format.
- Which images or clinical context are in scope? Modality: MRI Anatomy or clinical context: Cardiovascular/heart and aorta Input: DICOM cardiovascular MR images; QIR Suite also lists MR/CT DICOM handling functions.
- Who uses it? Intended users: Qualified medical professionals experienced in examining and interpreting cardiovascular MR images
- What does the software produce? Output: Visualization, segmentation, measurements, cardiac-function and flow analyses, and automated reports.
- What is its most important limitation? Key limitation: Validated for adults; not for patients; cannot replace diagnosis or serve as the sole medical viewpoint; final diagnosis remains the practitioner's responsibility.
Clinical takeaway
Clinical role: View, post-process, and quantitatively evaluate cardiovascular MR images in DICOM format.
Evidence takeaway
Evidence from the reviewed source record: FDA reports software verification/validation and predicate-comparison testing across datasets and 1.5/3T field strengths; no clinical study was required.
Clinical details
What this tool is for
Start with the authorized purpose, then verify how it fits your service line and reading workflow.
- Exact purpose
- View, post-process, and quantitatively evaluate cardiovascular MR images in DICOM format.
Clinical-use display mirrors the exact FDA-supported purpose reconciled in this remediation finding.
- Intended users
- Qualified medical professionals experienced in examining and interpreting cardiovascular MR images
FDA intended-user wording.
- Care setting and population
- Adult
Patient-population text reported in the exact-submission ACR model card; institutional setting may still require vendor confirmation.
- Workflow role
- Segmentation or contouring
Conservative normalization of explicit wording in an exact-submission source.
- Required input
- DICOM cardiovascular MR images; QIR Suite also lists MR/CT DICOM handling functions.
FDA indications and functionality list.
- Output and human action
- Visualization, segmentation, measurements, cardiac-function and flow analyses, and automated reports.
FDA functionality list.
- Limitations
- Validated for adults; not for patients; cannot replace diagnosis or serve as the sole medical viewpoint; final diagnosis remains the practitioner's responsibility.
FDA indications-for-use limitation boundary.
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
- FDA submission
- K211611
- Modality
- MRI
FDA intended use is cardiovascular MR; other functions list MR/CT DICOM handling.
- Anatomy
- Cardiovascular/heart and aorta
FDA lists four-chamber cardiac analyses and an aorta study.
- Clearance type
- 510(k)
- Decision date
- 2022-09-30
- FDA status
- FDA-cleared
Implementation
Questions for IT, informatics, and operations
Use these fields to structure a vendor demo, security review, and implementation estimate.
- Integration
- The exact-submission ACR model card explicitly references DICOM, PACS, and HL7 in the described input, output, or workflow; exact interfaces, versions, and local compatibility require confirmation.
Interoperability terms explicitly reported in the exact-submission ACR model card; interface versions and local compatibility still require confirmation.
- Deployment and data flow
- On-premise
Deployment category preserved from the prior exact-submission review; hosting region, data flow, and current commercial configuration still require vendor confirmation.
- Security and privacy
- Vendor documentation pending
Exact-release security controls, data retention, hosting boundaries, and scoped assurance documentation require vendor confirmation.
- Training and support
- Vendor documentation pending
Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.
- Monitoring and change control
- Vendor documentation pending
Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.
Result destination
PACS is explicitly referenced as a result destination.
exact submission · checked 2026-09-01Confirm supported products, versions, routing behavior, and display requirements during local evaluation.
Supported acquisition environment
Scanner manufacturers: All
exact submission · checked 2026-09-01Confirm currently supported software versions, protocols, and site-specific acquisition configurations.
ACR exact-submission catalog context
ACR AI Central provides an exact-submission model card for QIR Suite; FDA labeling remains controlling for clinical use, limitations, and performance.
exact submission · checked 2026-09-09Evidence
Performance evidence
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
- Evidence summary
- FDA reports software verification/validation and predicate-comparison testing across datasets and 1.5/3T field strengths; no clinical study was required.
Submission-reported performance summary.
- Reported sensitivity
- Research pending
This field has not been curated yet.
- Reported specificity
- Research pending
This field has not been curated yet.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
QIR Suite regulatory performance study summary
- DesignStand-Alone Performance
- PopulationAdult
- Scopeexact submission
- Tested versionExact product version not reported; regulatory study summarized for FDA submission K211611
- IndependenceIndependence not established
K211611
ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.
Costs and setup
Budget and ongoing governance
These are common procurement questions; unknown values remain visible until a source supports them.
- Pricing and total cost
- Vendor documentation pending
No public price or quote for the exact K211611 configuration was established in this review.
- Reimbursement and coding
- Not established in reviewed sources
No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.
Safety and lifecycle
Postmarket record
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
- Postmarket safety review
- The exact-identifier FDA recall query returned no native recall record for K211611. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
Buyer worksheet
Open questions to take to the vendor
- Verify security and privacy controls: Exact-release security controls, data retention, hosting boundaries, and scoped assurance documentation require vendor confirmation.
- Verify training: Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.
- Verify pricing and total cost: No public price or quote for the exact K211611 configuration was established in this review.
- Verify reimbursement and coding relevance: No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.
- Verify local validation and lifecycle monitoring: Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.
Research record
What has been checked
This audit distinguishes completed source review from fields that have not yet been researched.
Exact FDA record reviewedStatus
2026-09-20Last searched
25Fields reviewed
10Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads
The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, acr ai central product, fda device recall, literature index, trial registry, fda decision summary packet, pubmed, clinical trials, openfda device recall
Sources & history
How this profile was documented
Open the ledger for source dates, scope, and research-record updates.
View source ledger and history
Source ledger
-
FDA K211611: QIR Suite
Scope: identity, clinicalUse, modality, anatomy, workflow, evidence, implementation, purpose, intendedUsers, input, output, limitations, evidenceSummary
-
Artificial Intelligence-Enabled Medical Devices
Scope: regulatoryIdentity, modalityContext
-
QIR Suite model card (K211611)
Scope: intendedUsers, careSetting, output, limitations, evidenceSummary, integration, anatomy, evidenceStudies, implementationCapabilities
-
PubMed biomedical literature index
Scope: evidenceDiscovery
-
ClinicalTrials.gov study registry
Scope: evidenceDiscovery, studyStatus
-
openFDA Device Recall API
Scope: recallDiscovery, nativeSubmissionMatching
-
openFDA exact recall query for K211611
Scope: postmarketSafety
Research history
-
K211611 FDA decision
Regulatory record
510(k)
-
Source-review record updated
Research record
fda record reviewed
-
Reader overview source-reviewed
Editorial review
Source-reviewed editorial overlay
Alternatives
Related tools to compare
FDA-cleared K252084
AI4CMR v2.0
Ai4medimaging Medical Solutions S.A.
Cardiac MRI ventricular function and 2D phase-contrast flow quantification
- Modality
- MRI
- Anatomy
- Heart/Cardiovascular
- Decision
- 2026-02-11
FDA-cleared K241922
Myomics
Phantomics Inc.
Myomics assists qualified medical professionals with viewing, post-processing and qualitative/quantitative evaluation of 3T cardiovascular MR images in DICOM format, including...
- Modality
- MRI
- Anatomy
- Heart/Cardiovascular
- Decision
- 2025-02-28
FDA-cleared K241312
TeraRecon Cardiac.Chambers.MR (1.0.0)
TeraRecon,Inc.
Provide cardiac-chamber segmentations for trained healthcare professionals reviewing adult cardiac MR to assist diagnosis or treatment planning; the physician makes final...
- Modality
- MRI
- Anatomy
- Cardiac chambers: left-ventricular myocardium and chamber, and right-ventricular chamber for the Cine-ax component; left-ventricular myocardium and chamber for the De-ax component.
- Decision
- 2024-11-05
FDA-cleared K232661
Myocardial Strain Software Application
Circle Cardiovascular Imaging
Myocardial Strain Software Application provides qualitative and quantitative evaluation of cardiovascular MR images, including two-dimensional displacement, velocity, strain,...
- Modality
- MRI
- Anatomy
- Heart; left ventricular myocardium and cardiovascular structures
- Decision
- 2023-12-07